Ezetimibe

Ezetimibe is a selective cholesterol absorption inhibitor and the founding member of a pharmacological class that targets the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein at the brush border membrane of small intestinal enterocytes and on the canalicular membrane of hepatocytes. Developed at the Schering-Plough Research Institute through a medicinal chemistry program that originated in acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor optimization, the compound was identified as SCH 58235 and advanced to regulatory approval by the United States Food and Drug Administration in October 2002 for the treatment of primary hypercholesterolemia, homozygous familial hypercholesterolemia, homozygous sitosterolemia, and mixed hyperlipidemia. At the standard oral dose of 10 mg in the published literature, ezetimibe reduces intestinal cholesterol absorption by approximately 54 percent, produces a 15 to 22 percent reduction in low-density lipoprotein cholesterol (LDL-C) as monotherapy, and provides an incremental 23 to 24 percent LDL-C reduction when added to ongoing statin therapy. The molecular mechanism involves direct binding to NPC1L1, a polytopic transmembrane protein with sterol-sensing domains homologous to the Niemann-Pick type C1 protein (NPC1), blocking the clathrin/AP2-mediated endocytosis of the NPC1L1-cholesterol complex and thereby preventing cholesterol translocation from the intestinal lumen into the enterocyte cytoplasm.

The pharmacokinetic profile is dominated by rapid absorption followed by extensive first-pass glucuronidation to the pharmacologically active ezetimibe-glucuronide conjugate, which constitutes 80 to 90 percent of circulating drug. Both ezetimibe and its glucuronide undergo enterohepatic recirculation, producing a prolonged effective half-life of approximately 22 hours that supports dosing. Metabolism is mediated principally by uridine 5'-diphosphate-glucuronosyltransferase (UGT) isoenzymes 1A1, 1A3, and 2B15, with minimal cytochrome P450 involvement, conferring a favorable drug-drug interaction profile relative to the statin class. Approximately 78 percent of the administered dose is excreted in feces, predominantly as parent ezetimibe, with the remainder recovered in urine as the glucuronide conjugate.

The clinical evidence base for ezetimibe is anchored by two landmark cardiovascular outcomes trials. The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), published in 2015, randomized 18,144 patients with recent acute coronary syndrome to simvastatin plus ezetimibe versus simvastatin plus placebo and demonstrated a statistically significant 6.4 percent relative reduction in the primary composite cardiovascular endpoint (hazard ratio 0.936, p = 0.016) at a median follow-up of six years, establishing ezetimibe as the first non-statin lipid-lowering agent to demonstrate incremental cardiovascular benefit when added to statin therapy [1]. The SHARP trial (Study of Heart and Renal Protection) randomized approximately 9,270 patients with chronic kidney disease to simvastatin plus ezetimibe versus placebo and demonstrated significant reduction in major atherosclerotic events [2]. These trials collectively validated the LDL-C hypothesis beyond the statin class and positioned ezetimibe as a standard component of guideline-directed lipid management.

This monograph reviews the chemistry, synthesis, and structural pharmacology of ezetimibe; the NPC1L1 transporter biology and molecular mechanism of action; the comprehensive human pharmacokinetic record; the preclinical efficacy data in atherosclerosis and hypercholesterolemia models; the clinical evidence base across cardiovascular outcomes, chronic kidney disease, and combination therapy; sourcing and quality verification considerations; reconstitution and handling; stack interactions with statins, fibrates, bile acid sequestrants, and PCSK9 inhibitors; adverse events and safety signal including hepatic and musculoskeletal considerations; and a comparative assessment of five alternative non-statin lipid-lowering agents (bempedoic acid, evolocumab, alirocumab, inclisiran, colesevelam) against ezetimibe on five competency standards.